EpiTET Therapeutics
Biotechnology company developing first-in-class, oral small-molecule molecular glue degraders that selectively target and eliminate pathogenic macrophages for the treatment of chronic inflammatory diseases. Research focus includes target discovery, preclinical studies and peer-reviewed publications in areas such as endometriosis, metabolic liver disease (MASH) and cancer.
Industries
N/A
Services
In-house R&D of macrophage-targeted therapeutics
Research and preclinical development of selective macrophage-targeted small-molecule therapeutics.
In-house R&D of macrophage-targeted therapeutics
Research and preclinical development of selective macrophage-targeted small-molecule therapeutics.
Expertise Areas
- Molecular glue degrader development
- Macrophage-targeted therapeutics
- Inflammation and immunology
- Target discovery and validation
Key Technologies
- Molecular glue degrader platforms
- Small-molecule oral therapeutics
- Macrophage-targeting strategies
- Target discovery and validation methods